Navigation Links
Breckenridge Pharmaceutical Settles 'Paragraph IV' Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
Date:1/11/2008

BOCA RATON, Fla., Jan. 11 /PRNewswire-FirstCall/ -- Breckenridge Pharmaceutical, Inc. announced today that it settled "Paragraph IV" litigation with Novartis concerning Trileptal(R) and that the U.S. Food and Drug Administration approved Breckenridge's Abbreviated New Drug Application for oxcarbazepine 150mg, 300mg and 600 mg tablets in the United States ("Oxcarbazepine Tablets").

Breckenridge enjoys a shared 180-day exclusivity period and will immediately launch Oxcarbazepine Tablets 150 mg, 300 mg, and 600 mg. Oxcarbazepine Tablets are AB rated to Trileptal(R), a $600 million brand name drug marketed by Novartis Pharmaceuticals Corporation, and are used in treating seizures.

Breckenridge is actively seeking development and marketing alliances with domestic and foreign companies for generic and branded pharmaceuticals.

Breckenridge products are contract manufactured through partnerships with pharmaceutical manufacturers in state-of-the-art facilities throughout the U.S. Breckenridge maintains a stringent Quality Assurance program to ensure a consistent supply of quality pharmaceutical products.

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a privately-held pharmaceutical marketing research and development company founded in 1983, is headquartered in Boca Raton, FL, with offices in Berlin, CT, and Fairfield, NJ. Breckenridge markets over 100 products in many therapeutic categories to over 100 customers in all classes of trade.

Trileptal(R) is a registered trademark of Novartis Pharmaceuticals Corporation


'/>"/>
SOURCE Breckenridge Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG (Hamburg, Germany)
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
4. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
5. Patient-Centric Healthcare Study Reveals Key Insights for Pharmaceutical Marketers
6. KV Pharmaceutical Company Announces NYSE Listing Extension
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
8. Pharmaceutical Sales: Best Practices for Pharmaceutical Sales Success
9. NPS Pharmaceuticals to Present at the JPMorgan 26th Annual Healthcare Conference on January 9, 2008
10. Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America
11. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
(Date:6/23/2017)... Washington, D.C. (PRWEB) , ... June 23, 2017 ... ... temperature during cooking is essential, and two new videos highlight the importance of ... Extension Specialist Christine Bruhn, Ph.D., who has done extensive research on consumer food ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ... the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people ... the Biggert-Waters Act was enacted to reflect the actual risk in flood zone ...
(Date:6/23/2017)... Gilmer, TX (PRWEB) , ... June 23, 2017 , ... ... consultations to residential and business clients throughout eastern Texas, is announcing the launch of ... , Recent breast cancer statistics in the United States reveal that an estimated ...
(Date:6/22/2017)... IN (PRWEB) , ... June 22, 2017 , ... ... benefits advisory organization, is pleased to welcome Whipple & Company as its newest ... the clear purpose of balancing their clients’ risk while tailoring optimized benefit packages ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health ... it will be presenting at the 7th annual LD Micro Invitational ... Raphael , CEO, of DarioHealth will be giving the presentation and ... June 6th & 7th, 2017 at the Luxe Sunset Bel Air ... space. About LD Micro LD ...
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
Breaking Medicine Technology: